Tirzepatidi kannabiksen käyttöhäiriön hoidossa

Inclusion Criteria:

• English speaking adults aged 18 and above
• Diagnosed with DSM-5 cannabis use disorder, severe

Exclusion Criteria:

• Active psychosis, active suicidality or homicidality or any psychiatric condition that impair ability to provide informed consent
• Any current or lifetime diagnosis of eating disorders including anorexia, bulimia, binge eating or
• Comorbid substance use disorder
• BMI<21 kg/m2
• Current or lifetime diagnosis of Type 1 or Type 2 diabetes
• Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
• Use of any glucagon-like peptide -1 agonist medications in the prior 3 months
• Anticipating receipt of any glucagon-like peptide-1 agonist medications during the trial
• Current hypoglycemia as indicated by a blood sugar level of <71 mg/dL measured at baseline visit, as well as visits 2 and 4.
• Untreated cholelithiasis or gallbladder disease
• History of acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, or congestive heart failure in the last 90 days
• Systolic blood pressure persistently above 160 mmHg or diastolic blood pressure persistently above 100 mmHg during screening
• History of inflammatory bowel disease, bariatric surgery, pancreatitis, diabetic gastroparesis, or non-arteritic anterior ischemic optic neuropathy
• Liver function test greater than 3 times upper normal limit
• Renal impairment as indicated by estimated glomerular filtration rate (eGFR) of <30
• History of hypersensitivity or allergy to tirzepatide
• Pregnant or breastfeeding
• Individuals taking glucagon-like peptide-1 agonists or other weight loss drugs.
• Anticipated to participate in a concurrent drug trial
• Any other reason or clinical condition that the investigators judge may interfere with study participation and/or be unsafe for a participant